Broadfin Capital’s KalVista Pharmaceuticals KALV Stock Holding History

Broadfin Capital’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-143,129	Closed	-$2.83M	–	45
2018 Q4	$2.83M	Sell	143,129 -6,871	-5%	-$138K	0.37%	44
2018 Q3	$3.32M	Buy	+150,000	New	+$2.03M	0.49%	43
2016 Q1	–	Sell	-84,210	Closed	-$4.27M	–	81
2015 Q4	$4.27M	Hold	84,210	–	–	0.26%	72
2015 Q3	$4.21M	Hold	84,210	–	–	0.23%	70
2015 Q2	$8.43M	Buy	+84,210	New	+$8.36M	0.45%	50

Other funds holding KALV

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

VMI

VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Broadfin Capital's KALV Position: Q1 2019 in Review

Broadfin Capital sold out of KalVista Pharmaceuticals (KALV) in Q1 2019, closing a stake of 143,129 shares — an estimated $2.83M sold.

Broadfin Capital first reported a position in KALV in Q2 2015 and held it in 5 quarters. The position peaked at $8.43M in Q2 2015. 68 funds tracked by Wall St. Rank hold KALV as of Q1 2019.

Broadfin Capital reported no remaining KalVista Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Broadfin Capital sold 143,129 KalVista Pharmaceuticals shares in Q1 2019, an estimated $2.83M.
Broadfin Capital first reported a position in KalVista Pharmaceuticals in Q2 2015 and held it in 5 quarters.
Broadfin Capital's KalVista Pharmaceuticals position peaked at $8.43M in Q2 2015.
68 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2019.

Based on Broadfin Capital's 13F filing for Q1 2019, filed 15 May 2019.